Viewing Study NCT00281034

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 2:39 AM

Ignite Modification Date: 2025-12-26 @ 1:17 AM

Study NCT ID: NCT00281034

Status: COMPLETED

Last Update Posted: 2012-04-12

First Post: 2006-01-23

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)

Sponsor: Kyorin Pharmaceutical Co.,Ltd

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Overview

Official Title: Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS Study)

Status: COMPLETED

Status Verified Date: 2012-04

Last Known Status: None

Delayed Posting: No

If Stopped, Why?: Not Stopped

Has Expanded Access: False

If Expanded Access, NCT#: N/A

Has Expanded Access, NCT# Status: N/A

Acronym: None

Brief Summary: 1. To survey the health-related quality of life using the SF-36v2 score of patients with chronic brain infarction in Japan
2. Chronic brain infarction in Japan is better than EU/USA

Detailed Description: Period:2005-2007

Observation Time:baseline, 8week, 24week

matters investigated:

1. QOL determination using SF-36 v2
2. Age, sex, brain infarction type, stroke severity (modified Rankin scale), side of stroke, complication, smoking, alcohol, dizziness-vertigo-presyncope-light headedness, combination medicine, subjective symptoms, psychic symptoms, rehabilitation, recurrence, evaluation of depression (Japan-Stroke Scale (JSS)-D)

Study Oversight

Has Oversight DMC: True

Is a FDA Regulated Drug?: None

Is a FDA Regulated Device?: None

Is an Unapproved Device?: None

Is a PPSD?: None

Is a US Export?: None

Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID	Type	Domain	Link	View

oasis-2007	None	None		View